Abstract:Abstract Lung cancer is the leading cause of cancer-related deaths worldwide. Patients have few therapeutic options, and disease progression is inevitable. Anti-PD-1/PD-L1 antibodies can induce potent anti-tumor immunity and have been approved as a first-line therapy for non-small cell lung cancer (NSCLC). However, only ~20% of all NSCLCs benefit from checkpoint blockade, underscoring the critical need for the development of new and innovative approaches to identify actionable therapeutic targets to treat NSCLC. We identified the Transmembrane Serine Protease TMPRSS11B as a novel gene that promotes the transformation of human bronchial epithelial cells in vitro and induces tumorigenesis in vivo (Updegraff et al., Cell Reports, 2018). Our data show that TMPRSS11B promotes solubilization of Basigin, an obligate chaperone of the lactate monocarboxylate transporters MCT1 and MCT4, and that TMPRSS11B interacts and co-localizes with Basigin and MCT4. Moreover, Basigin release mediated by TMPRSS11B enhances lactate export and glycolytic metabolism, thereby promoting tumorigenesis. This is of significant interest because TMPRSS11B is frequently overexpressed in human lung squamous cell cancers (LSCC) and high expression is associated with poor survival of NSCLC patients. Moreover, as a cell surface protein and enzyme, TMPRSS11B represents an exciting putative target for therapeutic intervention. Our new studies demonstrate that the catalytic activity of TMPRSS11B may be important for the interaction with Basigin and enhanced lactate export. We also evaluated the effect of Tmprss11b depletion in the KLN205 syngeneic LSCC mouse model. CRISPR/Cas9 knockout of Tmprss11b in KLN205 LSCC cells significantly reduced tumor burden in immunocompetent DBA/2 WT mice. Moreover, mass spectrometry analysis revealed TMPRSS11B-interacting proteins that may represent novel substrates of this enzyme. Current studies are focused on elucidating the molecular mechanisms through which TMPRSS11B promotes tumorigenesis and investigating the efficacy of TMPRSS11B inhibition in syngeneic and autochthonous mouse models of LSCC, where the effects on immune cell function will be assessed. Citation Format: Hari Shankar Sunil, Barrett Updegraff, Jingfei Zhu, Bret M. Evers, John D. Minna, Ralph J. Deberardinis, Trudy G. Oliver, Kathryn A. O'Donnell. Targeting a novel cell surface serine protease TMPRSS11B for lung cancer therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3685.

Lung Specific X Protein As a Novel Therapeutic Target for Lung Cancer

LunX-CAR T Cells As a Targeted Therapy for Non-Small Cell Lung Cancer.

Supplementary Figures 1-6 from Targeting LUNX Inhibits Non–Small Cell Lung Cancer Growth and Metastasis

Immunogenic Senescence Sensitizes Lung Cancer to LUNX-targeting Therapy

Diagnostic Utility of LunX Mrna in Peripheral Blood and Pleural Fluid in Patients with Primary Non-Small Cell Lung Cancer

A New Checkpoint Receptor Targets For Cancer Immunotherapy

TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment

XRCC2 driven homologous recombination subtypes and therapeutic targeting in lung adenocarcinoma metastasis

[LUNX mRNA in regional lymph nodes of non-small cell lung cancer patients by RT-PCR and its clinical significance]

XCR1: A Promising Prognostic Marker That Pinpoints Targeted and Immune-based Therapy in Hepatocellular Carcinoma

Exploring the Mechanism of Periplogenin in the Treatment of Lung Cancer Based on Network Pharmacology and Molecular Biology

XBP1- IGFBP3 Signaling Pathway Promotes NSCLC Invasion and Metastasis

Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging

Abstract 3685: Targeting a novel cell surface serine protease TMPRSS11B for lung cancer therapy

Novel Potential Therapeutic Targets of PTPN Families for Lung Cancer

Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer

Identifying potential targets for preventing cancer progression through the PLA2G1B recombinant protein using bioinformatics and machine learning methods

FOXA1, induced by RC48, regulates HER2 transcription to enhance the tumorigenic capacity of lung cancer through PI3K/AKT pathway

XCR1 Promotes Cell Growth and Migration and is Correlated with Bone Metastasis in Non-Small Cell Lung Cancer.

The CDK1-Related lncRNA and CXCL8 Mediated Immune Resistance in Lung Adenocarcinoma